University of Exeter
exeter.ac.ukTotal trials
136
Active
26
Phase 3
0
Total enrollment
21,477
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lipopolysaccharide | — | — | — | — | — | 1 |
Next readouts
- 2026-08-31
Top conditions
- Healthy22
- Parkinson Disease7
- Neurodegenerative Diseases4
- Diabetes4
- Type 2 Diabetes4
- Stroke4
- Parkinson's3
- Parkinson's Disease3
Frequently asked questions about University of Exeter
- How many clinical trials does University of Exeter have on ClinicalTrials.gov?
- University of Exeter is listed as the lead sponsor on 136 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Exeter's trials are in Phase 3?
- 0 of University of Exeter's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does University of Exeter focus on?
- University of Exeter's most-studied conditions on ClinicalTrials.gov are Healthy, Parkinson Disease, Neurodegenerative Diseases, Diabetes, Type 2 Diabetes.
- When are University of Exeter's next clinical trial readouts?
- University of Exeter has 1 upcoming primary-completion readout tracked here; the soonest is “Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR”, expected around 2026-08-31.